Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GlaxoSmithKline ( (GB:GSK) ) just unveiled an update.
GlaxoSmithKline (GSK) has announced the purchase of 482,507 of its own ordinary shares, as part of its ongoing share buyback program. The shares, purchased at a volume-weighted average price of 1,419.08 pence, will be held as treasury shares. This transaction, executed through Merrill Lynch International, is part of a non-discretionary agreement initiated on June 4, 2025. Following this purchase, GSK holds 231,827,063 shares in treasury, with 4,083,556,994 shares in issue, excluding treasury shares. The buyback program aims to manage the company’s capital structure and return value to shareholders.
The most recent analyst rating on (GB:GSK) stock is a Buy with a £2610.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
GlaxoSmithKline’s overall stock score reflects a stable financial performance with solid profitability and strategic initiatives like share buybacks and dividend increases. Despite technical analysis indicating bearish trends, the company’s fair valuation and positive earnings call sentiment support a moderately positive outlook.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
Average Trading Volume: 9,147,021
Technical Sentiment Signal: Buy
Current Market Cap: £56.67B
See more data about GSK stock on TipRanks’ Stock Analysis page.